307 related articles for article (PubMed ID: 32050037)
21. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
22. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
23. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.
Peleg N; Issachar A; Sneh Arbib O; Cohen-Naftaly M; Harif Y; Oxtrud E; Braun M; Leshno M; Barsheshet A; Shlomai A
J Viral Hepat; 2019 Nov; 26(11):1257-1265. PubMed ID: 31243878
[TBL] [Abstract][Full Text] [Related]
24. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
[TBL] [Abstract][Full Text] [Related]
25. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
26. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
Azzi J; Dorival C; Cagnot C; Fontaine H; Lusivika-Nzinga C; Leroy V; De Ledinghen V; Tran A; Zoulim F; Alric L; Gournay J; Bronowicki JP; Decaens T; Riachi G; Mikhail N; Soliman R; Shiha G; Pol S; Carrat F; Ganne-Carrié N;
Clin Res Hepatol Gastroenterol; 2022; 46(6):101923. PubMed ID: 35405354
[TBL] [Abstract][Full Text] [Related]
27. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
[TBL] [Abstract][Full Text] [Related]
28. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
29. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
30. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.
Kim NJ; Vutien P; Cleveland E; Cravero A; Ioannou GN
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1723-1738.e5. PubMed ID: 35525392
[TBL] [Abstract][Full Text] [Related]
31. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal M; Piñero F; Ridruejo E; Herz Wolff F; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Videla Zuain MG; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Rubinstein F; Cheinquer H; Silva M; ;
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2554-2563.e3. PubMed ID: 32113892
[TBL] [Abstract][Full Text] [Related]
32. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
33. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.
Shiha G; Waked I; Soliman R; Elbasiony M; Gomaa A; Mikhail NNH; Eslam M
Liver Int; 2020 Nov; 40(11):2828-2833. PubMed ID: 32946647
[TBL] [Abstract][Full Text] [Related]
34. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
36. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
You MW; Kim KW; Shim JJ; Pyo J
J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
[TBL] [Abstract][Full Text] [Related]
37. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
38. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
Shirai K; Hikita H; Sakamori R; Doi A; Tahata Y; Sakane S; Kamada Y; Murai K; Nishio A; Yamada R; Kodama T; Nozaki Y; Kakita N; Ishida H; Nakanishi F; Morishita N; Imanaka K; Sakakibara M; Tatsumi T; Miyoshi E; Takehara T
PLoS One; 2022; 17(12):e0279416. PubMed ID: 36542633
[TBL] [Abstract][Full Text] [Related]
39. Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals.
Rodprasert N; Hongboontry T; Cherdchoochart C; Chaiteerakij R
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984603
[No Abstract] [Full Text] [Related]
40. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
